Filing Flows › Health Care › Koru Medical Systems (KRMD)
Koru Medical Systems (KRMD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · Koru Medical Systems (KRMD) Q2 2026 earnings results →
Q2 2026 Revenue up 18% year over year to $12.0M · 2¢ of every $1 of revenue kept as net profit · operating margin 5.2%
Koru Medical Systems made $12.0M in Q2 2026 (+18% Y/Y). Operating margin 5.2%, net earnings $252K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12.0M in Q2 2026, up 18% year over year and up 2% from the previous quarter.
Gross margin was 65.1%, up 1.6 points from Q2 2025. Operating profit was $627K, a 5.2% margin (up 8.3 points year over year). Operating expenses grew 6% against revenue growth of 18%. The fastest-growing cost line was SG&A (+10%). Net earnings were $252K. The effective tax rate was 2.2%.
Operating cash flow was $216K, 86% of net earnings. Non-cash charges added back $210K of depreciation and amortization and $458K of share-based compensation. Working capital and other items used $704K. Capital expenditures of $108K left free cash flow of $108K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $12.0M | +18% | 5.2% | $252K | $216K |
| Q1 2026 | 10-Q | May 6, 2026 | $11.8M | +22% | -7.4% | −$807K | $15K |
| Q4 2025 | 10-K | Mar 12, 2026 | $10.9M | +23% | -5.0% | −$487K | $1.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $10.4M | +27% | -8.3% | −$778K | $65K |
| Q2 2025 | 10-Q | Aug 6, 2025 | $10.2M | +21% | -3.1% | −$207K | −$460K |
| Q1 2025 | 10-Q | May 7, 2025 | $9.6M | +18% | -12.9% | −$1.2M | −$237K |
| Q4 2024 | 10-K | Mar 12, 2025 | $8.8M | +23% | -18.0% | −$1.6M | $940K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Koru Medical Systems
KORU Medical develops, manufactures and commercializes innovative and patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality system management. Our focus is primarily concentrated on our mechanical infusion products, the FREEDOM Infusion Systems (which we refer to as the “FREEDOM System” when used with one or more accessories), which include the FREEDOM60® Syringe Driver, the FreedomEdge® Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets™ and Precision Flow Rate Tubing™.
In its own words, from its 10-K, filed Mar 12, 2026.
Koru Medical Systems against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +18% against the peers' median +5%. Operating margin: 5.2% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KRMD Koru Medical Systems | Q2 2026 | $12.0M | +18% | 5.2% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Koru Medical Systems 10-Q on SEC EDGAR · CIK 704440 · Surgical & Medical Instruments & Apparatus
13F: who owns KRMD and who is buying
More on KRMD
- How Koru Medical Systems makes money: revenue by segment
- Koru Medical Systems next earnings date and what analysts expect
- Koru Medical Systems stock forecast, price target and fair value
- Who owns Koru Medical Systems stock: holders, funds and Congress trades
- Koru Medical Systems recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results